Washington, Oct 30 : A University of Denver (DU) study has revealed thatAxis Bank’s Q3FY26 performance marks a return to earnings normalcy, free of one-off distortions, even as margin pressures persist in a shifting rate environment.
News in Focus
Featured, Analyst View, Futures & Options, Stock Markets, Banking Sector, Axis Bank, ICICI Direct, India
Coforge Limited delivered a mixed operational performance in Q3FY26, missing revenue and profitability estimates, yet reinforcing its long-term investment thesis through a sharply expanding order b
DLF's Q3FY26 performance may appear underwhelming at first glance, but a deeper examination suggests that the company’s long-term growth trajectory remains firmly intact.
Axis Securities has reiterated its BUY call on Kotak Mahindra Bank Limited, assigning a target price of Rs 515, implying an upside of 22% from current levels.
Indian Bank’s Q3FY26 performance underscores a phase of measured consolidation rather than aggressive expansion.
Dr Reddy’s Laboratories is navigating a critical transition phase as legacy gains from gRevlimid taper off, even as the company lays the groundwork for its next multi-year growth cycle.
Main Regional Stories
UltraTech Cement, India’s largest cement manufacturer, continues to outpace industry growth as capacity expansion, operational efficiencies, and infrastructure-led demand converge into a multi-year growth cycle.
Featured, Analyst View, Stock Markets, BP Equities, Gujarat, Gujarat Themis Biosyn, India, Pharmaceutical Sector
Gujarat Themis Biosyn Limited (GTBL), a niche pharmaceutical manufacturer specializing in fermentation-based intermediates, is entering a decisive phase of strategic evolution. BP Equities Pvt. Ltd.
Motilal Oswal Financial Services has reiterated a BUY call on Suzlon Energy, arguing that the recent correction in the stock has created a compelling risk-reward setup at a time when India’s renewable energy architecture is quietly re-tilting in f
ICICI Direct has reiterated its BUY recommendation on SRF Limited, setting a 12-month target price of Rs 3,315, implying an upside of 21 percent from current levels.
